CYTH News and Press, Cyclo Therapeutics Inc. From 03/04/21

Cyclo Therapeutics (CYTH) announces that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously to patients with Niemann-Pick Disease Type C1 ((NPC1)), ...

Topline results from Phase 1/2 study on track for March 2021 Individual and cumulative data seen to-date show Trappsol ® Cyclo™ to be well tolerated with a favorable safety profile for all dose groups and to have encouraging signals in efficacy Pivotal ...

Cyclo Therapeutics (CYTH) traded 7.8% higher premarket on appointing Gerald F. Cox, MD, PhD as acting chief medical officer; Dr. Cox has 20+ years of experience in drug development for rare diseases."As we continue to advance our Trappsol Cyclo clinical developme...

- Seasoned biotechnology executive with 20-year successful track record of drug development for rare genetic diseases and extensive worldwide regulatory experience - Internationally renowned for clinical development of innovative drugs with broad experience in small molecules,...

- The evolution of the Company’s brand identity aligns with Cyclo Therapeutics’ science-based, patient-focus approach to drug development - Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Nieman...

Cyclo Therapeutics' lead compound is a hydrogen peroxide and peroxynitrite scavenger which may help in the treatment of Alzheimer's disease and other neurological conditions. Trappsol Cyclo appeared to either stabilize or produce improvements in Niemann-Pick type C disease patients, b...

Finding a treatment that can actually slow the progression of Alzheimer's disease has been referred to as the "holy grail" of drug development.The highway of Alzheimer's drug development is littered with failed candidates that have largely targeted the buildup of beta amyloid, a protein in th...

Data from ongoing Phase 1 extension study shows improvement in disease features or disease stabilization with home-based intravenous infusions of Trappsol ® Cyclo™ Phase 1 biomarker 24S-hydroxycholesterol demonstrates clearance of excess cholesterol from the br...

Shares of Anavex Life Sciences (AVXL), Cassava Sciences (SAVA), and Cyclo Therapeutics (CYTH) are all down significantly in afternoon trading.The biopharmas, all of which are working on candidates to treat Alzheimer's disease, have had the quite the run-up this week.In the last five days, Ana...

Gainers: T2 Biosystems (TTOO) +30%, Zomedica (ZOM) +24%, Sientra (SIEN) +18%, Misonix (MSON) +18%, Senseonics (SENS) +17%.Losers: Pro-Dex (PDEX) -22%, Veru (VERU) -21%, Twist Bioscience TWST -20%, Spero Therapeutics SPRO -19%, C...